Related Experiment Video
Updated: Jul 22, 2025

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Nanoparticle approaches for the renin-angiotensin system
Sajini D Hettiarachchi1, Young M Kwon1, Yadollah Omidi1
1Department of Pharmaceutical Sciences, Barry and Judy College of Pharmacy, Nova Southeastern University, 3200 S University Dr, Davie, FL, 33328 USA.
Abstract:
The renin-angiotensin system (RAS) is a hormonal cascade that contributes to several disorders: systemic hypertension, heart failure, kidney disease, and neurodegenerative disease. Activation of the RAS can promote inflammation and fibrosis. Drugs that target the RAS can be classified into 3 categories, AT1 angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, and renin inhibitors. The therapeutic efficacy of current RAS-inhibiting drugs is limited by poor penetration across the blood-brain barrier, low bioavailability, and to some extent, short half-lives. Nanoparticle-mediated drug delivery systems (DDSs) are possible emerging alternatives to overcome such limitations. Nanoparticles are ideally 1-100 nm in size and are considered efficient DDSs mainly due to their unique characteristics, including water dispersity, prolonged half-life in blood circulation, smaller size, and biocompatibility. Nano-scale DDSs can reduce the drug dosage frequency and acute toxicity of drugs while enhancing therapeutic success. Different types of nanoparticles, such as chitosan, polymeric, and nanofibers, have been examined in RAS-related studies, especially in hypertension, cardiovascular disease, and COVID-19. In this review article, we summarize the physical and chemical characteristics of each nanoparticle to elaborate on their potential use in RAS-related nano-drug delivery research and clinical application.
Insights
Nanoparticle drug delivery systems offer a promising solution to overcome limitations of current renin-angiotensin system (RAS) inhibitors. These nano-scale systems enhance drug efficacy and reduce toxicity for treating RAS-related disorders.
Area of Science:
- Biomedical Engineering
- Pharmacology
- Nanotechnology
Background:
- The renin-angiotensin system (RAS) plays a critical role in systemic hypertension, heart failure, kidney disease, and neurodegenerative disorders.
- RAS activation can exacerbate inflammation and fibrosis, contributing to disease progression.
- Current RAS-inhibiting drugs face challenges including poor blood-brain barrier penetration, low bioavailability, and short half-lives.
Purpose of the Study:
- To review nanoparticle-mediated drug delivery systems (DDSs) as potential alternatives to overcome limitations of conventional RAS inhibitors.
- To summarize the physical and chemical characteristics of various nanoparticles for RAS-related applications.
- To elaborate on the potential clinical applications of nano-scale DDSs in managing RAS-associated diseases.
Main Methods:
- Review of existing literature on nanoparticle DDSs and their application in targeting the renin-angiotensin system.
- Analysis of nanoparticle characteristics such as size, water dispersity, circulation half-life, and biocompatibility.
- Examination of different nanoparticle types, including chitosan, polymeric, and nanofibers, used in RAS-related studies.
Main Results:
- Nanoparticle DDSs exhibit unique characteristics like smaller size (1-100 nm), enhanced water dispersity, prolonged circulation, and biocompatibility.
- Nano-scale DDSs can potentially reduce drug dosage frequency and acute toxicity while improving therapeutic outcomes.
- Various nanoparticles have shown promise in studies related to hypertension, cardiovascular disease, and COVID-19, all involving RAS.
Conclusions:
- Nanoparticle-mediated DDSs represent a significant advancement for RAS-targeted therapies, addressing limitations of traditional drugs.
- The unique properties of nanoparticles offer enhanced efficacy and safety profiles for treating a range of RAS-related conditions.
- Further research into the physical and chemical properties of nanoparticles is crucial for optimizing their use in clinical applications for RAS disorders.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Hormonal Regulation
Hypertension II: Pathophysiology

